NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer

SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and the Parker Institute for Cancer Immunotherapy (PICI) announced today that they are collaborating on an expansive molecular characterization project for cellular therapies. The collaboration will define the characteristics...

Click to view original post